HSCT for MS: How Stem Cell Therapy Resets the Immune System

Autologous hematopoietic stem cell transplantation (HSCT) is one of the most aggressive treatments available for multiple sclerosis, and the evidence increasingly supports its use in well-selected patients. The procedure essentially reboots the immune system: a patient’s own stem cells are harvested, chemotherapy wipes out the faulty immune cells attacking the nervous system, and the stored stem cells are re-infused to rebuild the immune system from scratch. Studies show it can achieve higher rates of disease-free status than standard MS drugs, with treatment-related mortality now well below one percent at experienced centers.

How the Immune Reset Actually Works

The logic behind HSCT for MS starts with what drives the disease. In MS, immune cells, particularly T cells, mistakenly attack the myelin coating around nerve fibers. Standard disease-modifying therapies try to restrain or redirect those immune cells. HSCT takes a more radical approach: it eliminates the existing immune system and lets a new one grow from the transplanted stem cells.

Research tracking the immune system’s recovery after transplant shows that this reset is thorough but uneven. CD4+ T cells (the “helper” cells that coordinate immune attacks) are largely replaced by a new repertoire. The dominant clones that existed before treatment become undetectable, and the patient develops what is essentially a fresh set of CD4+ cells. CD8+ T cells (the “killer” cells) are a different story: dominant CD8+ clones survive the conditioning chemotherapy and repopulate through clonal expansion, meaning some of the old immune memory persists. CD4+ cells remain below pre-treatment levels for at least two years, while CD8+ cells bounce back faster.

This distinction matters. The replacement of the CD4+ repertoire is thought to be a key reason HSCT halts the inflammatory attacks in MS. The persistence of CD8+ cells, meanwhile, helps explain why the immune system still functions after transplant: patients are not left permanently immunocompromised the way they would be after an organ transplant. Over time, the reconstituted immune system appears to “forget” its previous targeting of myelin, which is why many patients remain relapse-free for years.

Who Gets the Best Results

Not every MS patient is a good candidate, and the research is fairly consistent on who benefits most. Patients with relapsing-remitting MS, younger age, lower disability scores, and shorter disease duration at the time of transplant tend to have the best outcomes. These factors align with guidelines from the European Society for Blood and Marrow Transplantation (EBMT), which has published formal recommendations on patient selection.² A review in Nature Reviews Neurology put it plainly: patients most likely to benefit are young, still able to walk, and have active inflammatory disease.³

The practical takeaway is that HSCT works best when the disease is still being driven by inflammation rather than by neurodegeneration that has already caused irreversible damage. Patients with progressive MS can still respond, but the response rates are lower. In one single-center study, the overall response rate (defined as either disability improvement or stabilization) was about 83% for relapsing-remitting patients, compared to 78% for primary progressive and 73% for secondary progressive MS.⁴ Those are still notable numbers for progressive MS, where most available drugs show limited benefit, but the gap reinforces the general message: earlier treatment tends to produce better results.

How HSCT Compares to Standard MS Drugs

The comparison most patients and neurologists care about is how HSCT stacks up against the high-efficacy disease-modifying therapies that have become standard for aggressive relapsing MS. A major observational study published in JAMA Neurology compared HSCT directly to fingolimod, natalizumab, and ocrelizumab in patients with highly active relapsing-remitting MS. Over five years, HSCT patients had fewer relapses than those on fingolimod and were roughly two and a half times more likely to experience disability improvement. Compared to natalizumab, HSCT had a slightly lower relapse rate and a similarly elevated chance of disability improvement. Against ocrelizumab, the results over three years were largely similar for relapses, disability worsening, and disability improvement.⁵

A broader review of published studies reached the same general conclusion: HSCT achieves higher rates of no evidence of disease activity (NEDA) compared to disease-modifying therapies, with a lower annualized relapse rate and the potential to slow progressive disease.⁶ NEDA is the composite measure neurologists use as a benchmark: no relapses, no new MRI lesions, and no worsening disability. In some cohorts of relapsing-remitting patients, NEDA rates at five years after HSCT have ranged from about 70% to 80%.

The picture with ocrelizumab deserves extra attention because it is now considered the strongest of the conventional high-efficacy drugs for MS. The JAMA Neurology data showed HSCT and ocrelizumab performing comparably over a shorter follow-up window. Whether HSCT maintains a durable advantage over ocrelizumab at longer time horizons remains an open question, and a randomized head-to-head trial would be needed to settle it definitively.

Which Conditioning Regimen Matters

Before stem cells are returned to the patient, the existing immune system is suppressed with a chemotherapy-based conditioning regimen. Two approaches dominate practice: BEAM combined with anti-thymocyte globulin (ATG), and high-dose cyclophosphamide combined with ATG. There has been ongoing debate about whether one is superior to the other.

A large retrospective analysis from the EBMT’s Autoimmune Diseases Working Party compared the two. At five years, the rate of NEDA failure was about 42% in the BEAM/ATG group and about 44% in the cyclophosphamide/ATG group, a difference that was not statistically significant. After adjusting for disease type, baseline disability, and transplant year, the two regimens showed no clear separation in efficacy or toxicity.⁷ This is reassuring because it means the choice of regimen can be guided by center experience and patient-specific factors rather than a rigid one-size-fits-all protocol.

What Happens to Disability and Daily Life

Beyond the technical disease metrics, what patients want to know is whether they will feel and function better. The evidence here is encouraging, though the degree of improvement varies. In a prospective phase II trial, sustained improvement in disability scores was seen in about 44% of patients.⁸ A larger single-center series found that nearly half of patients reported disability improvement and another third reported stabilization, with the mean disability score falling from about 5.1 to 4.5 points in the first year.⁹

Fatigue, one of the most disabling and underappreciated symptoms of MS, also tends to improve. One study found that a composite fatigue score dropped by about 36% after transplant, and four patients experienced a complete resolution of fatigue. Younger patients and those with lower disability at baseline improved the most, and the improvement correlated with real-world functional gains like returning to work and resuming driving.¹⁰ Separately, a study tracking quality of life after HSCT found significant improvement in physical functioning, vitality, and pain within three months, with those gains sustained at two years. Fatigue improvement took about a year to emerge but also persisted.¹¹

Safety, Short-Term Risks, and Mortality

The most common objection to HSCT for MS has always been safety. Chemotherapy conditioning carries real risks, and early programs saw treatment-related mortality rates of roughly 1 to 2%. That figure has fallen substantially as centers gained experience and patient selection improved. Current data from large international registries indicate that treatment-related mortality is now well below 1% at experienced transplant centers, and some individual programs report zero treatment-related deaths.¹²

Short-term complications resemble those seen in autologous transplants performed for cancers like lymphoma. Patients experience a period of low blood counts, nausea, hair loss, and vulnerability to infections during the weeks immediately following chemotherapy. MS patients face a few unique wrinkles. Urinary tract infections are more common because many patients already have bladder dysfunction and require catheterization during treatment. Patients who receive anti-thymocyte globulin or CD34-selected grafts are also at risk for reactivation of latent herpes viruses, including varicella-zoster (shingles), Epstein-Barr virus, and cytomegalovirus. Antiviral prophylaxis is standard practice to manage those risks.¹³

Long-Term Complications Worth Knowing About

Beyond the acute transplant period, one of the more underappreciated risks is the development of new autoimmune diseases. When the immune system rebuilds from scratch, it occasionally produces immune responses directed at new targets. Autoimmune thyroid disease, particularly Graves’ disease, is the most commonly reported secondary autoimmune condition after HSCT for MS, typically appearing within roughly 8 to 32 months after transplant. Estimates of how often this happens range from about 2% to 14% of patients, with thyroid disease accounting for the majority of cases.¹⁴

Other secondary autoimmune conditions have been reported less frequently, including autoimmune thrombocytopenia, where the immune system attacks platelets. These conditions are generally treatable, but they do require ongoing monitoring. The EBMT guidelines recommend regular follow-up, including periodic thyroid function testing, for several years after transplant.¹⁵

The Cost Equation

HSCT is expensive upfront, but the cost comparison shifts dramatically over time because it is a one-time treatment. High-efficacy disease-modifying therapies are taken continuously, often for decades. A European cost-effectiveness analysis found that HSCT and high-efficacy drugs cost about the same over two years, but over five years HSCT was roughly half the price: about €46,600 compared to €93,800 for the drugs. The gap was even more striking when looking at cost per NEDA outcome, where drugs cost about five times more over five years.¹⁶

In the U.S. context, a separate analysis found that the cost of non-myeloablative HSCT (a milder conditioning approach) after which patients discontinued drugs indefinitely was roughly equal to one year of prescription disease-modifying therapy. Given that drugs are taken on an ongoing basis while HSCT is not, the treatment is expected to produce long-term cost savings.¹⁷ This is a genuine advantage, particularly for younger patients who might otherwise face 30 or 40 years of drug costs.

What Blood Biomarkers Show

One of the more compelling lines of evidence for HSCT comes from biomarker studies measuring neurofilament light chain (NfL), a protein that leaks into the blood when nerve fibers are damaged. High NfL levels are a hallmark of active neurodegeneration in MS. After HSCT, elevated NfL levels in both blood and cerebrospinal fluid drop significantly, falling to levels indistinguishable from healthy controls.¹⁸

A study tracking multiple biomarkers over five years found that NfL concentrations fell from a mean of 920 pg/mL at baseline to 270 pg/mL at five years. Myelin basic protein, a marker of active demyelination, also dropped substantially. Interestingly, GFAp, a marker associated with astrocytic damage, did not change, suggesting that while HSCT effectively halts the inflammatory attack on myelin and nerve fibers, it does not reverse all forms of nervous system injury.¹⁹ This is consistent with the clinical observation that HSCT is better at stopping new damage than at repairing old damage, which is another reason earlier treatment tends to produce better outcomes.

Fertility and Pregnancy After Transplant

Chemotherapy conditioning raises legitimate concerns about fertility, and this is an especially important topic given that HSCT candidates tend to be young adults. The evidence on pregnancy after HSCT for MS is still limited, but what exists is reassuring. In one ongoing phase II trial, 30 women of childbearing age underwent transplant. Four pregnancies occurred afterward: two were carried to term without maternal or neonatal complications, and two were electively terminated. Among the 21 male patients, one fathered three children after his transplant, all without newborn complications.²⁰

These numbers are too small to draw sweeping conclusions, but they show that pregnancy is possible after HSCT and can result in healthy outcomes. Fertility preservation, including egg or sperm banking before treatment, is standard practice at most transplant centers. Patients considering HSCT should discuss reproductive planning with their care team before the procedure, since the window for preservation is before conditioning chemotherapy begins. The timing of pregnancy after transplant also matters: most specialists recommend waiting at least a year, and preferably two, to ensure the immune system has adequately reconstituted and any post-transplant medications have been discontinued.